Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24338045 | 0.76 | ALDH1A1 (0.47) | ALDH1A1PKMDPP4KDM4EDPP8 | |
| SCHEMBL21986742 | 0.74 | ALDH1A1 (0.50) | ALDH1A1PKMDPP4KDM4EDPP8 | |
| SCHEMBL21986813 | 0.74 | DPP4 (0.58) | ALDH1A1PKMDPP4KDM4EDPP8 | |
| SCHEMBL21986783 | 0.71 | IDO1 (0.37) | — | |
| SCHEMBL3855175 | 0.68 | MEN1 (0.42) | ALDH1A1PKMDPP4LMNAMEN1 | |
| SCHEMBL28345433 | 0.68 | CYP1A2 (0.33) | ALDH1A1KDM4E | |
| SCHEMBL18405893 | 0.66 | LMNA (0.38) | ALDH1A1PKMDPP4LMNAPDE2A | |
| SCHEMBL26290092 | 0.66 | NOS2 (0.36) | ALDH1A1KDM4E | |
| SCHEMBL4607622 | 0.65 | LMNA (0.40) | ALDH1A1PKMDPP4KDM4EDPP8 | |
| SCHEMBL18964905 | 0.65 | LMNA (0.40) | ALDH1A1PKMDPP4LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660003-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-11713311-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-01 | — | — | US | disclosed |
| US-20220388995-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-08 | — | — | US | disclosed |
| US-11230541-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-25 | — | — | US | disclosed |
| US-20200231579-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-23 | — | — | US | disclosed |
| EP-3660003-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230541-B2 | Heterocyclic compound | GRIN1, GRIN2A, GRIN2B | ALDH1A1 3354/4885PKM 3693/4885DPP4 3639/4885 |
| US-20200231579-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRIN2A, GRIN2B | ALDH1A1 3354/4885PKM 3693/4885DPP4 3639/4885 |
| US-11713311-B2 | Heterocyclic compound | GRIN1, GRIN2A, GRIN2B | ALDH1A1 3354/4885PKM 3693/4885DPP4 3639/4885 |
| US-20220388995-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRIN2A, GRIN2B | ALDH1A1 3354/4885PKM 3693/4885DPP4 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.